Difference between revisions of "Rest AP-Zuclopenthixol LA"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugswitch | from = Rest AP | to = Zuclopenthixol_LA | stop = {{Downslweeks}} | start = {{StartDepot}} | view = | info = {{Alternatief}} }}')
 
Line 4: Line 4:
 
| stop = {{Downslweeks}}
 
| stop = {{Downslweeks}}
 
| start = {{StartDepot}}
 
| start = {{StartDepot}}
| view =  
+
| view = empty.jpg
 
| info = {{Alternatief}}
 
| info = {{Alternatief}}
 
}}
 
}}

Revision as of 14:15, 19 August 2009

Rest anti-psychotics

Chlorprothixene
Flupentixol
Loxapine
Pericyazine
Perphenazine
Trifluoperazine
Ziprasidone
Zuclopenthixol

Zuclopenthixol
long acting
Type Antipsychotic
Group Thioxanthenes
links
PubChem 5311507
PubMed Zuclopenthixol
Kompas (Dutch) Zuclopenthixol
Wikipedia Zuclopenthixol

Switch medication from Rest AP to Zuclopenthixol_LA.[1] [2]

Nietinrijdenbord.png Stop Rest AP
  • Week 1-3: approx. 75% of initial dose
  • Week 4-6: approx. 50% of initial dose
  • Week 7-9: approx. 25% of initial dose
  • Week 10: stop
Eenrichtingbord.png Start Zuclopenthixol_LA
  • Day 1: Start depot according general dosing advice (Dotted line in graph)
Infobord.png More information
  • Alternatively, first switch to oral form and then switch to depot to manage possible (adverse) reactions. With a direct switch to a depot it is advisable to administer a low testdose in order to exclude adverse reactions.
    Empty.jpg
Nietinrijdenbord.png — Rest AP
Eenrichtingbord.png — Zuclopenthixol_LA


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.